AGIOS PHARMACEUTICALS, INC. (AGIO) [Rocket]

Overview

AGIOS PHARMACEUTICALS, INC. (AGIO)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
09/28/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
08/21/2023	4	Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
08/15/2023	4	Ballal Rahul D. (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
08/15/2023	4	Smith Cynthia (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
08/11/2023	4	Foster-Cheek Kaye I (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
08/10/2023	4	Goff Brian (CEO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
08/09/2023	4	Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	14.2	0.0	0.0	0.0	94.4	43.0	69.9	59.1
Revenue growth				-100.0%	119.4%	-38.5%	18.2%	-9.7%
Cost of goods sold	1.7	0.0	0.0	0.0	1.4	0.0	0.0	0.0
Gross profit	12.5	0.0	0.0	0.0	93.0	43.0	69.9	59.1
Gross margin	88.0%				98.5%	100.0%	100.0%	100.0%
Selling, general and administrative	121.7	121.4	115.1	102.0	114.1	71.1	50.7
Research and development	279.9	257.0	220.8	214.3	341.3	292.7	220.2	141.8
General and administrative								36.0
EBIT	-389.0	-378.4	-335.9	-316.3	-362.5	-320.8	-201.0	-118.7
EBIT margin	-2732.1%				-384.0%	-745.8%	-287.6%	-200.8%
Pre-tax income	-231.8	-356.5	-329.3	-301.4	-346.0	-314.7	-198.5	-117.7
Income taxes	0.0	-1,961.2	-1.9	110.1	0.0	0.0	0.0	0.0
Tax rate	0.0%	550.1%	0.6%		0.0%	0.0%	0.0%	0.0%
Net income	-231.8	1,604.7	-327.4	-411.5	-346.0	-314.7	-198.5	-117.7
Net margin	-1627.8%				-366.6%	-731.6%	-284.0%	-199.1%

Diluted EPS	($4.23)	$26.55	($4.74)	($6.86)	($6.03)	($6.75)	($5.07)	($3.15)
Shares outstanding (diluted)	54.8	60.4	69.0	60.0	57.4	46.6	39.1	37.4

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.